Modality
ADC
MOA
JAK1/2i
Target
CDK4/6
Pathway
Cell Cycle
LN
Development Pipeline
Preclinical
~Oct 2013
→ ~Jan 2015
Phase 1
~Apr 2015
→ ~Jul 2016
Phase 2
~Oct 2016
→ ~Jan 2018
Phase 3
Apr 2018
→ Sep 2028
Phase 3Current
NCT08560224
567 pts·LN
2018-04→2028-09·Completed
567 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-11-174mo agoFast Track· LN
2028-09-122.5y awayPh3 Readout· LN
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P3
Complet…
Catalysts
Fast Track
2025-11-17 · 4mo ago
LN
Ph3 Readout
2028-09-12 · 2.5y away
LN
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08560224 | Phase 3 | LN | Completed | 567 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Fixanesiran | AbbVie | Preclinical | RET | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| Sovarelsin | BioMarin | Phase 2 | CFTR | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Niramavacamten | Hansoh Pharma | Phase 2 | SGLT2 | |
| Elralucimab | Axsome | Phase 2 | CDK4/6 | |
| Talazumab | Zealand Pharma | Phase 1/2 | WEE1 | |
| CGO-9628 | CG Oncology | Phase 2/3 | AuroraA |